Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00231270
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : April 24, 2008
Information provided by:
Cordis Corporation

Brief Summary:
The primary objective of this study is to compare the safety and effectiveness of the Cordis Nitinol Carotid Stent and Delivery Systems (5.5 F and 7 F) with the ANGIOGUARD XP distal protective device to CEA in the treatment of carotid artery disease in patients at increased risk for surgery.

Condition or disease Intervention/treatment Phase
Carotid Artery Disease Device: Cordis Nitinol Stent Device: PRECISE tapered stent Device: ANGIOGUARD XP Emboli Capture Guidewire (ECGW) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 1300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy
Study Start Date : August 2000
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. composite of major adverse clinical events including death, any stroke, and/or myocardial infarction at 30-days post-procedure [ Time Frame: 30-days post-procedure ]
  2. The same 30-day composite of major adverse clinical events plus death and/or ipsilateral stroke between 31-days and 12-months post-procedure. [ Time Frame: Between day 31 and 12-months post-procedure. ]

Secondary Outcome Measures :
  1. successful stent deployment at the target lesion in a variety of carotid morphologies
  2. successful filter deployment and retrieval
  3. <30% residual stenosis determined by angiography immediately post-stent placement and post-dilatation
  4. endovascular access site complications, such as the need for surgical repair or blood transfusion
  5. surgical site complications, such as wound infection or hematoma, that prolong hospital stay, require incision and drainage, or need blood transfusion
  6. patency (< 50% restenosis) of the Cordis Nitinol Stent as determined by carotid ultrasound imaging within 48 hours, at six months, and one, two and three years post-procedure
  7. independent neurologic assessments at 24 + 12 hours, thirty days, six months, and one, two and three years post-procedure (in addition to stroke scales, the development of any cranial nerve deficits will be recorded) - persistent neurologic deficits
  8. thirty (30)-day and six (6)-month evaluation for disabling stroke [ Time Frame: Day 30 and 6 months ]
  9. six (6)-month, one (1)-year, two (2)-year and three (3)-year composite of major adverse clinical events including death and ipsilateral stroke [ Time Frame: 6 month and 1, 2, 3yr ]
  10. safety assessment of the ANGIOGUARD XP Emboli Capture Guidewire Device
  11. presence of trapped material as determined by the interventionalist's visual inspection of the ANGIOGUARD XP filter basket following recapture at the completion of the procedure
  12. laboratory analysis of trapped material contained in the ANGIOGUARD XP filter basket

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The patient must be > 18 years of age.
  2. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:

    • one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or
    • one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis >50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR The patient must have a >80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms.
  3. To be entered into the study, the patient must have one or more of the following conditions:

    • congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%
    • open heart surgery within six weeks
    • recent MI (>24 hours and <4 weeks)
    • unstable angina (CCS class III/IV)
    • synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization
    • Age greater than 80 years as a single risk factor.

Exclusion Criteria:

  1. The patient is experiencing an acute ischemic neurologic stroke or has experienced a stroke within the past 48 hours.
  2. The patient has an intracranial mass lesion (i.e., abscess, tumor, or infection).
  3. The reference segment diameter (distal common carotid and internal carotid artery segment cephalic to the lesion) is less than 4mm or greater than 9mm by quantitative analysis. See Instructions For Use, for proper stent sizing. The exception to this would be with a lesion having >95% stenosis where the true diameter of the distal vessel can not be determined such as the case with a string sign or distal vessel collapse. In this case the judgment of the interventionalist will prevail with the intention not to oversize the stent to the distal vessel by more than 2mm.
  4. The patient has known peripheral vascular, supra-aortic or internal carotid artery tortuosity which preclude the use of catheter-based techniques if so randomized.
  5. The patient has any intracranial aneurysm (> 9 mm).
Publications of Results:
Layout table for additonal information Identifier: NCT00231270    
Other Study ID Numbers: P98-5201
First Posted: October 4, 2005    Key Record Dates
Last Update Posted: April 24, 2008
Last Verified: July 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases